Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib versus methotrexate in recurrent/metastatic head and neck cancer
NCT01856478Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2013
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Boehringer Ingelheim. Started Jun 2013; status: completed.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01856478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856478.